Oxcarbazepine (All indications) updated on 04-22-2025

Abruptio placentae (retroplacental hematoma)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9041
R30860		 Cohen (Oxcarbazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 Placental abruption early pregnancy retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: Yes 0.92 [0.47;1.80]
excluded (control group) 		17/1,109   50/2,682 67 1,109
ref
S9043
R30874		 Cohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 Placental abruption early pregnancy retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 0.92 [0.57;1.51] 17/1,109   20,269/1,440,631 20,286 1,109
ref
Total 1 studies 0.92 [0.57;1.50] 20,286 1,109
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Cohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019Cohen, 2019 1 0.92[0.57; 1.51]20,2861,1090%ROB confusion: moderateROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate0.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Controls unexposed NOS) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.92[0.57; 1.50]20,2861,109 -NACohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 1 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.92[0.57; 1.50]20,2861,109 -NACohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 1 Tags Adjustment   - Yes  - Yes 0.92[0.57; 1.50]20,2861,109 -NACohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 1 All studiesAll studies 0.92[0.57; 1.50]20,2861,109 -NACohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 10.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9041

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.92[0.57; 1.50]20,2861,109 -NACohen (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2019 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.92[0.47; 1.80]671,109 -NACohen (Oxcarbazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 10.510.01.0